F-1/A: NewGenIvf Group Limited Files Amendment to Registration Statement for Resale of 40 Million Class A Ordinary Shares

NewGenIvf Group Limited has filed an amendment to its registration statement for the resale of up to 40 million Class A Ordinary Shares by a selling shareholder, White Lion Capital, LLC.

Summary

• NewGenIvf Group Limited, a British Virgin Islands holding company, has filed an amendment to its registration statement for the resale of up to 40 million Class A Ordinary Shares.
• The shares are being offered by White Lion Capital, LLC, a selling shareholder, and were issued in connection with a Common Stock Purchase Agreement.
• The company will not receive any proceeds from the sale of these shares, but may receive up to $500 million from future sales of shares to White Lion under the purchase agreement.
• NewGenIvf is an assisted reproductive services provider with operations in Thailand, Cambodia, and Kyrgyzstan.
• The company's services include in vitro fertilization (IVF) treatments and surrogacy services.
• NewGenIvf's revenue for the year ended December 31, 2023 was $5,136,153, with a net income of $108,418.
• The company's revenue for the year ended December 31, 2022 was $5,944,190, with a net income of $135,847.
• The company is currently appealing a Nasdaq delisting determination and is seeking to transfer its listing to the Nasdaq Capital Market.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While the company has a strong market position and growth potential, it also faces significant challenges, including financial losses, potential delisting, and reliance on external funding. The sentiment is therefore cautiously negative.

Positives

• NewGenIvf has a strong presence in the Asia-Pacific region with clinics in Thailand, Cambodia, and Kyrgyzstan.
• The company offers a comprehensive range of assisted reproductive services, including IVF, egg donation, and surrogacy.
• NewGenIvf has an exclusive license for MicroSort technology in Thailand and Cambodia, providing a competitive advantage.
• The company has a track record of completing over 4,000 IVF treatment cycles.
• The company has a strong network of agents in China and India, which helps to drive patient referrals.
• The company has a experienced management team with considerable experience in the ARS market and the broader healthcare industry.

Negatives

• The company will not receive any proceeds from the resale of the shares by the selling shareholder.
• The company is facing a potential delisting from Nasdaq due to not meeting minimum market value requirements.
• The company has a history of net losses and may not sustain profitability in the future.
• The company's business is subject to various risks, including competition, regulatory changes, and economic conditions in the countries where it operates.
• The company has a limited operating history with its current platform of solutions, which makes it difficult to predict its future prospects.
• The company is reliant on revenue from international clients, which is subject to fluctuations in exchange rates and travel restrictions.

Risks

• The company may not be able to continue operating as a going concern.
• The company faces significant competition in the fertility market.
• The company has a limited operating history with its current platform of solutions.
• The company's marketing efforts depend on positive references from existing clients.
• The company may experience net losses and may not sustain profitability in the future.
• The company's future revenue may not grow at the rates it historically has, or at all.
• The company's quarterly and annual results may fluctuate significantly.
• The company may not be able to successfully manage its growth.
• The company may fail to adapt to the changing medical landscape and regulations.
• The company may fail to retain and motivate key employees.
• The company is subject to economic, legal and regulatory uncertainties in Thailand, Cambodia and Kyrgyzstan.
• The company requires a significant amount of capital to fund its operations and growth.
• The company may not be successful in adapting to technological developments.
• The company may not be able to comply with the filing deadlines for reports that it files pursuant to the Exchange Act.
• The company may be delisted from Nasdaq if it is unable to meet listing requirements.
• The company's business depends on its ability to maintain its network of high-quality fertility specialists.
• The company may be subject to claims and allegations relating to intellectual property and other causes.
• The company operates in a highly regulated industry and must comply with a significant number of complex and evolving requirements.
• The company is subject to anti-corruption, anti-bribery, anti-money laundering, and similar laws.

Future Outlook

The company plans to offer broad fertility services for fertility tourists, invest in laboratories and facilities, increase brand awareness, and expand service reach through acquisitions and partnerships.

Management Comments

• The Company will leverage several strategic options to regain compliance with the applicable Nasdaq listing requirements and ensure its securities remain publicly traded.
• The Company will apply to transfer its securities from the Nasdaq Global Market to the Nasdaq Capital Market.

Industry Context

The document highlights the growing demand for fertility services in the Asia-Pacific region, driven by factors such as later maternal age and increasing social acceptance of assisted reproductive technologies. The company is positioning itself to capitalize on this growing market.

Comparison to Industry Standards

• The document mentions that the average cost per IVF cycle in the US is around US$12,000, while NewGenIvf's average cost is around US$7,000, indicating a competitive pricing strategy.
• The document cites CIC data indicating that the Asia Pacific ARS market is growing at a strong pace of approximately 15% in 2022.
• The document cites CIC data indicating that only approximately 1.47 million ARS cycles were performed in Asia Pacific in 2022, while there were more than 213 million infertile couples, indicating significant unmet demand.

Related Party Transactions

• The company has engaged in transactions with related parties, including loans and remuneration to directors and shareholders.

Stakeholder Impact

• Shareholders face the risk of potential delisting and dilution.
• Employees may be affected by the company's financial performance and potential restructuring.
• Customers may be impacted by changes in service offerings or pricing.
• Suppliers may be affected by the company's financial stability and ability to pay.
• Creditors may be affected by the company's ability to repay its debts.

Next Steps

• The company will leverage several strategic options to regain compliance with the applicable Nasdaq listing requirements.
• The company will apply to transfer its securities from the Nasdaq Global Market to the Nasdaq Capital Market.
• The company may elect to sell shares to White Lion under the purchase agreement.

Key Dates

Keywords

assisted reproductive services, IVF, fertility treatments, surrogacy, MicroSort technology, Asia-Pacific, Nasdaq, delisting, White Lion Capital, equity line of credit